Evidence map›Paper›PMID 34104007›Full record

ReviewMedical devices (Auckland, N.Z.)2021

Avitene™ Microfibrillar Collagen Hemostat for Adjunctive Hemostasis in Surgical Procedures: A Systematic Literature Review.

David J Cziperle

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Medical devices (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07788846 (A Prospective, Randomized, Controlled, Assessor-Blinded, Three-Arm Clinical Trial Comparing Fibrillar Type-I Collagen Haemostat, Bone Wax, and Standardized Compression for Control of Cancellous Bone Marrow Bleeding Following Single-Ray Amputation), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07788846 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Prospective, Randomized, Controlled, Assessor-Blinded, Three-Arm Clinical Trial Comparing Fibrillar Type-I Collagen Haemostat, Bone Wax, and Standardized Compression for Control of Cancellous Bone Marrow Bleeding Following Single-Ray Amputation

TypeinterventionalSponsorDr Naveen Narayan MS, MCh (Plastic Surgery)Ran2026 to 2027Enrolled135ConditionsHemostasis, Surgical Blood Loss, Amputation Stump, HemorrhageArmsFibrillar type-I collagen haemostat, Bone wax, Standardised compression protocol
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Temporary Embolic Agents.Seminars in interventional radiology · 2024
    Review
  6. Article
  7. Review
  8. Embolic Agents: Particles.Seminars in interventional radiology · 2023
    Review
  9. Viable tendon neotissue from adult adipose-derived multipotent stromal cells.Frontiers in bioengineering and biotechnology · 2023
    Article
  10. Article
  11. Collagen as a Biomaterial for Skin and Corneal Wound Healing.Journal of functional biomaterials · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David J CziperleThoracic Surgery, Ann B. Barshinger Cancer Institute, Lancaster, PA, USA.ORCID 0000-0003-1745-7480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adequate hemostasis during surgical procedures is essential for successful patient outcomes and reduced healthcare resource utilization. Topical hemostatic agents can act as catalysts for the clotting cascade or as a scaffold to promote platelet activation or aggregation. Although an ever-increasing number of topical absorbable hemostatic agents are now available for perioperative use, health care providers are disadvantaged by the lack of comparative data on feasibility, clinical effectiveness, advantages, and limitations of each in specific surgical settings. This knowledge is important for appropriate product choice when patient characteristics, type of surgical procedure, type of bleeding, and product availability may differ widely. This manuscript provides the first comprehensive overview of Avitene™ Microfibrillar Collagen Hemostat (MCH), a bovine collagen-based absorbable hemostat that has been widely used for over four decades in the United States and abroad. MCH is indicated as an adjunct to hemostasis across a broad spectrum of surgical specialties and has been shown to achieve hemostasis with positive patient outcomes and a favorable safety profile in many applications, including hepatic, orthopedic, splenic, oral, and otolaryngologic surgery. Although published clinical data regarding the use of MCH in cardiovascular surgery is limited, evidence suggests moderate use in this specialty. The information contained in this systematic review will help health care providers understand the clinical use and effectiveness of the product to determine appropriate use in differing bleeding scenarios across multiple surgical specialties. Future studies may include comparative functional and cost analyses to explore the economic advantages of using absorbable hemostatic agents compared with each other or with conventional techniques of hemostasis, when appropriate.

Indexed as

Avitenehemorrhagehemostasismicrofibrillar collagensurgerytopical

Identifiers

PMID34104007
PMCPMC8179802
OpenAlexW3172373595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.